Skip to main content

Table 3 Treatment persistence and medication possession ratio administered by group

From: Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

Group Brand-name Generic Total p
Number of patients (%) 3007 (22.7%) 10, 237 (77.3%) 13,244 (100%)
Time since diagnosis (months) 2.2 (2.4) 2.2 (2.3) 2.2 (2.4) 0.892
 Median (P25–P75) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)  
Treatment possession (months) 22.3 (20.2) 19.6 (21.7) 20.2 (21.2) < 0.001
 Median (P25–P75) 21.0 (12.0–44.0) 19.0 (10.0–38.0) 20.0 (10.0–42.0)  
Treatment duration (months) 34.2 (20.5) 32.0 (20.2) 32.5 (20.3) < 0.001
 Median (P25–P75) 31.0 (15.0–60.0) 29.0 (14.0–55.0) 29.0 (14.0–56.0)  
Medication Possession Ratio
 Average 65.1% 61.5% 62.3% < 0.001
 95% CI 63.8–66.2% 60.1–62.2% 61.8–62.9%  
Percentage of patients on treatment at different cut-off point Treatment persistence (HR [95% CI])a
 12 months 80.3% 77.7% 78.3% 0.81 [0.74–0.89], p < 0.001
 24 months 60.9% 56.9% 57.8% 0.93 [0.87–0.99], p = 0.021
 60 months 25.9% 20.7% 21.9% 0.86 [0.82–0.91], p < 0.001
  1. Values expressed as percentage or mean (SD standard deviation), p brand-name vs. generic, CI confidence interval, P25 25th percentile, P75 75th percentile
  2. aHR adjusted hazard ratio relative to brand-name statin (adjusted using a Cox proportional risk model with covariates (age, sex, number of comorbidities, Charlson index, resource utilization band, proportion of subjects reaching their LDL-cholesterol goal at the start of therapy, statin type and prior cardiovascular event); P percentile